HPS Pharmacies wish to advise that Sanofi-Aventis Australia is experiencing a short-term supply interruption for Clexane® as follows:

Clexane® Syringe
Enoxaparin sodium 40 mg/0.4 mL
ARTG 221718

Normal supplies of Clexane® 40mg are expected to return by 24 June 2024. Exarane® 40mg is an alternative product that also contains enoxaparin 40mg/0.4mL in a ready-to-use pre-filled syringe. Exarane® 40mg is currently available in some states, but it is also experiencing a temporary supply interruption in some states.

Unlike Clexane® syringes, Exarane® does not have a safety lock system. If Exarane® is used, additional care is required to avoid needlestick injury. Patients or carers supplied Exarane® for self-injection should be educated on how to use the syringes safely. Patient counselling can be complemented with the provision of the consumer medicines information (CMI) document, which contains administration instructions.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Sanofi-Aventis Australia on 1800 818 806, or your pharmacist at HPS Pharmacies.

Download PDF

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates